Phase I study of combined indomethacin and platinum-based chemotherapy to reduce platinum-induced fatty acids
- 159 Downloads
Chemotherapy-resistance remains a major obstacle to effective anti-cancer treatment. We previously showed that platinum analogs cause the release of two fatty acids. These platinum-induced fatty acids (PIFAs) induced complete chemoresistance in mice, whereas co-administration of a COX-1 inhibitor, indomethacin, prevented PIFA release and significantly enhanced chemosensitivity. To assess the safety of combining indomethacin with platinum-based chemotherapy, and to explore its efficacy and associated PIFA levels, a multi-center phase I trial was conducted.
The study was comprised of two arms: oxaliplatin plus capecitabine (CAPOX, arm I) and cisplatin plus gemcitabine, capecitabine or 5FU (arm II) in patients for whom these regimens were indicated as standard care. Indomethacin was escalated from 25 to 75 mg TID, using a standard 3 × 3 design per arm, and was administered orally 8 days around chemo-infusion from cycle two onwards. PIFA levels were measured before and after treatment initiation, with and without indomethacin.
Thirteen patients were enrolled, of which ten were evaluable for safety analyses. In arm I, no dose-limiting toxicities were observed, and all indomethacin dose levels were well-tolerated. Partial responses were observed in three patients (30%). Indomethacin lowered plasma levels of 12-S-hydroxy-5,8,10-heptadecatrienoic acid (12-S-HHT), whereas 4,7,10,13-hexadecatetraenoic acid (16:4(n-3)) levels were not affected. Only one patient was included in arm II; renal toxicity led to closure of this cohort.
Combined indomethacin and CAPOX treatment is safe and reduces the concentrations of 12-S-HHT, which may be associated with improved chemosensitivity. The recommended phase II dose is 75 mg indomethacin TID given 8 days surrounding standard dosed CAPOX.
KeywordsChemotherapy resistance Mesenchymal stem cells Platinum-induced fatty acids Indomethacin Oxaliplatin
This work was supported by a Grant from the Dutch Cancer Society (KWF), Grant number UU 2012-5712, and received financial support rom the Swiss Advisory Board for Research EOC for study monitoring. The authors gratefully acknowledge the support of all four participating sites, and all study participants.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 3.The “Accidental” Cure—Platinum-based Treatment for Cancer: The Discovery of Cisplatin (2014) National Cancer Institute. https://www.cancer.gov/research/progress/discovery/cisplatin. Accessed 8 Aug 2017
- 11.Roodhart JM, Daenen LG, Stigter EC, Prins HJ, Gerrits J, Houthuijzen JM, Gerritsen MG, Schipper HS, Backer MJ, van Amersfoort M, Vermaat JS, Moerer P, Ishihara K, Kalkhoven E, Beijnen JH, Derksen PW, Medema RH, Martens AC, Brenkman AB, Voest EE (2011) Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acids. Cancer Cell 20(3):370–383. https://doi.org/10.1016/j.ccr.2011.08.010 CrossRefPubMedGoogle Scholar
- 13.Daenen LG, Cirkel GA, Houthuijzen JM, Gerrits J, Oosterom I, Roodhart JM, van Tinteren H, Ishihara K, Huitema AD, Verhoeven-Duif NM, Voest EE (2015) Increased plasma levels of chemoresistance-inducing fatty acid 16:4(n-3) after consumption of fish and fish oil. JAMA Oncol 1(3):350–358. https://doi.org/10.1001/jamaoncol.2015.0388 CrossRefPubMedGoogle Scholar
- 17.Greene SN, Ramos-Vara JA, Craig BA, Hooser SB, Anderson C, Fourez LM, Johnson BM, Stewart JC, Knapp DW (2010) Effects of cyclooxygenase inhibitor treatment on the renal toxicity of cisplatin in rats. Cancer Chemother Pharmacol 65(3):549–556. https://doi.org/10.1007/s00280-009-1061-2 CrossRefPubMedGoogle Scholar
- 22.Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (Oxf 1990) 45(2):228–247. https://doi.org/10.1016/j.ejca.2008.10.026 CrossRefGoogle Scholar
- 23.Stigter EC, Letsiou S, vd Broek NJ, Gerrits J, Ishihara K, Voest EE, Verhoeven-Duif NM, Brenkman AB (2013) Development and validation of a quantitative LC-tandem MS assay for hexadeca-4,7,10,13-tetraenoic acid in human and mouse plasma. J Chromatogr B Anal Technol Biomed Life Sci 925:16–19. https://doi.org/10.1016/j.jchromb.2013.01.012 CrossRefGoogle Scholar
- 24.Ishihara K, Murata M, Kaneniwa M, Saito H, Komatsu W, Shinohara K (2000) Purification of stearidonic acid (18:4(n-3)) and hexadecatetraenoic acid (16:4(n-3)) from algal fatty acid with lipase and medium pressure liquid chromatography. Biosci Biotechnol Biochem 64(11):2454–2457CrossRefPubMedGoogle Scholar
- 30.Knapp W, Glickman DW, Widmer NR, Denicola W, Adams DG, Kuczek L, Bonney TL, DeGortari PE, Han A, Glickman C L (2000) Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer. Cancer Chemother Pharmacol 46(3):221–226. https://doi.org/10.1007/s002800000147 CrossRefPubMedGoogle Scholar
- 31.Kohne CH, De Greve J, Hartmann JT, Lang I, Vergauwe P, Becker K, Braumann D, Joosens E, Muller L, Janssens J, Bokemeyer C, Reimer P, Link H, Spath-Schwalbe E, Wilke HJ, Bleiberg H, Van Den Brande J, Debois M, Bethe U, Van Cutsem E (2008) Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. Ann Oncol 19(5):920–926. https://doi.org/10.1093/annonc/mdm544 CrossRefPubMedGoogle Scholar
- 32.Pierga J, Delaloge S, Giacchetti S, Brain E, Savignoni A, Sigal-Zafrani B, Mathieu M, Bertheau P, Guinebretière J, De Cremoux P, Spyratos F, Marty M (2009) A multicenter randomized phase ii study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patient. Cancer Res 69(24 Supplement):5054–5054. https://doi.org/10.1158/0008-5472.sabcs-09-5054 CrossRefGoogle Scholar